### REVIEW

**6909** Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms

*Wu ZY, Li YL, Chang B*

### MINIREVIEWS

**6923** Emerging use of artificial intelligence in inflammatory bowel disease

*Kohli A, Holzwanger EA, Levy AN*

### ORIGINAL ARTICLE

#### Basic Study

**6929** Development and validation of a three-long noncoding RNA signature for predicting prognosis of patients with gastric cancer

*Zhang J, Piao HY, Wang Y, Lou MY, Guo S, Zhao Y*

**6945** Artificial intelligence based real-time microcirculation analysis system for laparoscopic colorectal surgery

*Park SH, Park HM, Baek KR, Ahn HM, Lee IV, Son GM*

**6963** Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer

*Li Y, Wang JS, Guo Y, Zhang T, Li LP*

#### Case Control Study

**6979** Fatty liver is an independent risk factor for gallbladder polyps


#### Retrospective Cohort Study

**6993** Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America

*Fortes FML, Boa Sorte N, Mariano VD, Andrade LD, Oliveira FA, Santos MCA, dos Santos CIN, Passos CA, Pacheco MP, Surlo VC, de Almeida NP, Fontes JAM, Pimentel AM, Rocha R, Santana GO*

#### Retrospective Study

**7005** Hepatocellular carcinoma with tumor thrombus in bile duct: A proposal of new classification according to resectability of primary lesion

*Zhou D, Hu GF, Gao WC, Zhang XY, Guan WB, Wang JD, Ma F*

**7022** Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer

*Cheong C, Shin JS, Suh KW*
Contents

World Journal of Gastroenterology

Weekly Volume 26 Number 44 November 28, 2020

7036 Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perforation after endoscopic papillectomy: A pilot study
   Wu L, Liu F, Zhang N, Wang XP, Li W

Observational Study

7046 Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome
   Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G

Prospective Study

7061 Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study
   Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB

CASE REPORT

7076 COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report

LETTER TO THE EDITOR

7085 Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’
   Elzubeir A, Alam SM
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Dr. Diego Garcia-Compeán is a Distinguished Professor of Internal Medicine and Gastroenterology at Faculty of Medicine, Autonomous University of Nuevo Leon Mexico, where he received his degree in Medicine (1979) and completed postgraduate training in Internal Medicine (1982). He studied gastroenterology at the University of Montpellier, France (1985) and received a Master’s in Medical Sciences with cum laude honors from the National Autonomous University of Mexico (1988). He is currently a member of the National Research System, level II, the Mexican Association of Gastroenterology, the Société Nationale Française de Gastroenterologie, the AGA, and the LAASL. His ongoing research interests involve NAFLD, eosinophilic esophagitis, liver cirrhosis, and VCE. He has published more than 75 papers in international journals, edited 3 books, and obtained national and international awards. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ji-Hong Liu; Production Department Director: Yun-Xiaojian Wu; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
November 28, 2020

COPYRIGHT
© 2020 Baishideng Publishing Group Inc
Emerging use of artificial intelligence in inflammatory bowel disease

Arushi Kohli, Erik A Holzwanger, Alexander N Levy

ORCID number: Arushi Kohli 0000-0002-9974-4821; Erik A Holzwanger 0000-0001-7747-7729; Alexander N Levy 0000-0002-6293-0380.

Author contributions: Kohli A performed the majority of the writing, prepared the figures and tables; Holzwanger EA performed editing and proofreading; Levy AN provided the input in writing the paper and designed the outline.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Specialty type: Gastroenterology

Arushi Kohli, Department of Internal Medicine, Tufts Medical Center, Boston, MA 02111, United States

Erik A Holzwanger, Alexander N Levy, Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA 02111, United States

Corresponding author: Alexander N Levy, MD, Assistant Professor, Attending Doctor, Division of Gastroenterology and Hepatology, Tufts Medical Center, 800 Washington Street, Box 233, Boston, MA 02111, United States. a levy@tufts medical center.org

Abstract

Inflammatory bowel disease (IBD) is a complex, immune-mediated gastrointestinal disorder with ill-defined etiology, multifaceted diagnostic criteria, and unpredictable treatment response. Innovations in IBD diagnostics, including developments in genomic sequencing and molecular analytics, have generated tremendous interest in leveraging these large data platforms into clinically meaningful tools. Artificial intelligence, through machine learning facilitates the interpretation of large arrays of data, and may provide insight to improving IBD outcomes. While potential applications of machine learning models are vast, further research is needed to generate standardized models that can be adapted to target IBD populations.

Key Words: Artificial intelligence; Machine learning; Automated diagnostics; Colorectal neoplasia screening; Multiomic data; Predictive models

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Artificial intelligence (AI) is a novel technological advancement that is rapidly growing in the field of inflammatory bowel disease. The use of AI and machine learning has been shown to aid in diagnosing and understanding severity of disease, predicting treatment response along with likelihood of disease recurrence and assisting with colorectal neoplasia screening in this patient population. Further studies are needed to understand the full impact AI may have on improving Crohn’s disease and ulcerative colitis patient outcomes.

Citation: Kohli A, Holzwanger EA, Levy AN. Emerging use of artificial intelligence in inflammatory bowel disease. World J Gastroenterol 2020; 26(44): 6923-6928
INTRODUCTION

Inflammatory bowel disease (IBD), comprised of ulcerative colitis (UC) and Crohn’s disease (CD), is a set of chronic, immunologically-mediated diseases of the gut that arise from a complex interaction of host genetics, their environment, and gut microbiome[1]. Due to its chronic relapsing nature, IBD is associated with considerable morbidity and impairment of quality of life.

Accurate diagnosis of IBD relies on a combination of clinical, endoscopic, histologic, laboratory, and radiographic data. Significant heterogeneity exists in both the quality of these critical diagnostic components and their subsequent interpretation, as they are inherently dependent on confounders, such as the technical skill and experience of the provider. Consequently, diagnostic algorithms and management of IBD can vary considerably amongst gastroenterologists.

Recently, “big data” from large clinical trials, electronic health records, medical imaging, biobanks, and multiomic (genomic, transcriptomic, metabolomic, and proteomic) databases have been increasingly employed in an effort to improve diagnostic accuracy and predictability of treatment response[2]. However, the use of big data in development of predictive models is confounded by high dimensionality of clinical and non-clinical factors[3]. To overcome this challenge, machine learning (ML) has been increasingly utilized to organize and interpret these large datasets in an effort to identify clinically meaningful patterns and translate them into improved patient outcomes[4]. This review highlights the nascent efforts to incorporate artificial intelligence (AI) and machine learning in the field of IBD.

MACHINE LEARNING

AI is an interdisciplinary branch of computer science focused on the development of machines that are programmed to perform tasks that imitate intelligent human behavior[5]. Machine learning is a subset of AI that utilizes algorithms with the goal of identifying patterns or generating predictive models as a result of “learning” from an input dataset[6]. This is achieved through supervised and unsupervised learning (Figure 1). In supervised learning, an algorithm is trained on a labeled training dataset to recognize patterns associated with specific groups (healthy vs diseased)[7]. The algorithm then uses what it has learned from the training dataset to place unseen data into specific categories. The most commonly employed supervised ML models are random forests, neuronal networks and support vector machines[8]. Unsupervised models use an unlabeled training dataset and the algorithm identifies patterns within the data guided by similar characteristics without knowledge of associated diagnosis or outcome[9]. Machine learning algorithms can provide a framework to identify previously undiscovered patterns within IBD and advance our understanding of IBD pathogenesis.

ADVANCES IN DIAGNOSTICS AND DISEASE SEVERITY ASSESSMENT

Endoscopic evaluation with mucosal biopsies remains an integral component to diagnosing IBD, yet it carries several limitations. In addition to being invasive, endoscopic assessment of disease severity remains subjective with high interobserver variability despite the use of scoring systems such as the endoscopic Mayo score. In addition, endoscopy may not be able to adequately distinguish between subtle overlapping features of the various IBD phenotypes, resulting in diagnostic dilemmas. Recent research has focused on integrating ML into the diagnostic paradigm in order to overcome some of these limitations.

Genome wide association studies have identified over 240 gene loci that have been linked to increased risk of developing IBD and can assist in distinguishing CD and UC[10]. Matrix factorization based ML models, using a combination of genome sequence data and biological knowledge have also been developed to distinguish patients with CD from healthy individuals (AUC = 0.816) without the need of
In addition, ML assisted metagenomic, proteomic, and microbial prediction models have been utilized to identify predictive signatures distinguishing CD and UC, allowing for improved characterization of the IBD subtypes and risk stratification\(^9\). For example, Seeley et al\(^11\) were able to discern between CD and UC with 76.9% accuracy using a histology based, mass spectrometry trained, support vector machine learning model by analyzing protein signatures from colonic tissue. Another study model used featured a selection algorithm combined with a support vector machine program to differentiate UC patients from healthy subjects based on the expression of 32 genes in colon tissue samples\(^12\).

Similarly, the inherent subjectivity of endoscopic and radiographic assessment has led to a great interest in automating image interpretation. ML assisted analysis of computed tomography and magnetic resonance imaging has been shown to effectively identify structural bowel damage, such as strictureing disease in CD\(^13-15\). Image analyzing programs have also been adapted to improve the efficiency of previously time consuming manual review of video capsule endoscopy images\(^16\).

AI has also been utilized to enhance interpretation of endoscopic images to assess disease severity\(^17-19\).

For example, a convolutional neural network (CNN) was able to distinguish remission (Mayo 0-1) from moderate-to-severe disease (Mayo 2-3) with a sensitivity of 83.0% and specificity of 96.0%\(^18\). Another CNN model was able to detect severe CD ulcerations with high accuracy, 0.91 for grade 1 vs grade 3 ulcers\(^20\). Computer-aided diagnosis systems have also been shown to reliably predict persistent histologic inflammation during endoscopy with a sensitivity of 74%, specificity 97%, and accuracy of 91%\(^21\).

Clearly, computer assisted imaging assessment has the potential to improve how we interpret diagnostic imaging to assess disease activity. As a result, it is expected that use of AI assisted imaging will continue to expand as the technology evolves.

### PREDICTION OF TREATMENT RESPONSE AND DISEASE RECURRENCE

Despite numerous pharmacologic advances over the past decade, clinicians are not yet able to predict treatment response in IBD. The prevailing trial and error approach has resulted in substantial variation in response rates to IBD therapy. This inefficiency, in combination with the significant pharmacoeconomic impact of failed therapies, has led to a growing interest in developing personalized approaches to IBD management.

To this end, machine learning algorithms have been developed to analyze predictive indicators of response for several IBD medications. One study was able to demonstrate that an ML algorithm could outperform conventional thiopurine metabolite testing to predict response\(^22\). Subsequent studies by Waljee et al\(^23,24\) incorporated clinical trial
data from the GEMINI I and GEMINI II studies with vedolizumab, and demonstrated that ML models could also be used to predict steroid free remission for UC and CD patients. In another study, a ML model used molecular and clinical data to identify biomarkers predictive of response to infliximab in refractory UC (accuracy = 70%). The authors identified tumor necrosis factor, interferon gamma, and lipopolysaccharide as potential regulators of infliximab response[25]. More recently, multi-omic factor analysis was used to identify transcriptomic and genomic biomarker panels that were predictive of ustekinumab response[26].

**COLORECTAL NEOPLASIA SCREENING**

As a result of chronic inflammation, IBD patients are at increased risk for dysplasia and colorectal cancer. Patients with extensive colitis have up to a 19-fold increase in colorectal cancer risk when compared to the general population[27]. Despite the introduction of high-definition endoscopes and dye-based chromoendoscopy, the morbidity and mortality ascribed to IBD neoplasia has led to great interest in integrating AI-assisted detection systems into traditional colonoscopy. Multiple AI algorithms have been developed to alert the endoscopist of polyps in real-time, using visual or auditory cues during colonoscopy[28]. CNNs have been successfully used to improve adenoma detection in the general population, even for more experienced endoscopists[29]. The CNN model, when compared to expert review of machine-overlaid videos, had a sensitivity and specificity of 0.98 and 0.93, respectively[30].

Another computer-aided diagnosis system detected polyps by evaluating polyp boundaries and generating energy maps that corresponded to the presence of a polyp[31]. Machine learning may also aid in differentiation of colitis associated neoplasia, sporadic colorectal adenomas, and non-neoplastic lesions[32]. Artificial neuronal networks, when applied to complimentary deoxyribonucleic acid microarray data, have the potential to discriminate the subtle differences between polyp subtypes[32]. This may have longstanding effects on decreasing colorectal malignancy and may also guide surveillance in this population.

**LIMITATIONS OF ARTIFICIAL INTELLIGENCE**

While AI has the ability to identify high risk subgroups and inform treatment decisions, there remain several obstacles to its routine implementation into clinical practice. Analysis of big datasets have generated several interesting disease observations but these have not necessarily translated into clinically meaningful benefits. The cross-sectional nature of ML datasets, lack of validated AI models, and paucity of biologic explanations for proposed associations makes it difficult to establish causation or adhere to AI algorithm generated decision recommendations. Additionally, the datasets that machine learning systems are dependent upon can be incomplete or of poor quality which can result in systematic errors or bias[33].

The highly sensitive nature of clinical data makes it logistically difficult to share freely amongst organizations, an obstacle potentially overcome by universal electronic medical records. There is also a need for adherence to unified data formats, as well as development of secure cloud storage facilities for easy extraction of large volumes of data[33]. Furthermore, varying degrees of clinical data are in the form of written notes, making data collection for input into mathematical ML models difficult. This can be overcome by development of natural language processing software to extract data from plain text[34]. Other challenges include the high dimensionality of clinical data, over-fitting of ML models, data security issues, and reliability of models to be generalized to the target population[33].

Overcoming the obstacles to machine learning in IBD will require collaborative efforts between clinicians, statisticians, and bioinformaticians to develop algorithms capable of generating clinically meaningful outputs. Prospective randomized trials are needed to confirm the efficacy and safety of AI assisted decision making before it can truly be translated to the bedside.

**CONCLUSION**

In summary, AI is a rapidly growing discipline that has the potential to revolutionize
the field of inflammatory bowel disease. Machine learning approaches offer the ability to effectively synthesize and incorporate large amounts of data to improve diagnostic accuracy, uncover new disease associations, identify at risk individuals, and guide therapeutic decision making. While challenges to the routine use of AI in IBD remain, continued exploration of possible applications are expected to accelerate the drive toward precision medicine.

REFERENCES


